Beigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu Sells 51,921 Shares

Beigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu sold 51,921 shares of the company’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $281.40, for a total transaction of $14,610,569.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Xiaobin Wu also recently made the following trade(s):

• On Wednesday, March 5th, Xiaobin Wu sold 51,921 shares of Beigene stock. The shares were sold at an average price of $261.59, for a total value of $13,582,014.39.
• On Thursday, February 20th, Xiaobin Wu sold 21,267 shares of Beigene stock. The stock was sold at an average price of $240.07, for a total value of $5,105,568.69.
• On Tuesday, February 18th, Xiaobin Wu sold 30,654 shares of Beigene stock. The shares were sold at an average price of $240.74, for a total value of $7,379,643.96.

Beigene Stock Performance

ONC opened at $264.32 on Friday. Beigene, Ltd. has a 1-year low of $126.97 and a 1-year high of $287.88. The stock has a market capitalization of $26.07 billion, a price-to-earnings ratio of -32.08, a P/E/G ratio of 7.73 and a beta of 0.65. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05.

Beigene (NASDAQ:ONC) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.09 billion. As a group, equities research analysts predict that Beigene, Ltd. will post -5.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

ONC has been the subject of a number of analyst reports. Guggenheim reissued a “buy” rating on shares of Beigene in a report on Friday, February 28th. Sanford C. Bernstein set a $259.00 price target on shares of Beigene in a research report on Thursday, March 13th. Macquarie raised their price objective on shares of Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. JMP Securities set a $348.00 target price on Beigene in a report on Friday, February 28th. Finally, Bank of America raised Beigene from a “neutral” rating to a “buy” rating and raised their price target for the company from $207.00 to $320.00 in a report on Monday, March 3rd.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.